Abstracts tagged "Vasculitis"

Abstract Number: 2512 • ACR Convergence 2024
French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy
Kevin Chevalier¹, François Chasset², Yoann Zerbib³, Pierre-André Jarrot⁴, Romain Muller⁴, Thomas Pires⁵, Saroumadi Adavane⁶, Didier Bessis⁷, Alban Deroux⁸, Vincent Descamps⁹, Fanny Domont¹⁰, Joëlle Faddoul¹⁰, Pierre-Edouard gavand¹¹, Tiphaine Goulenok¹², Baptiste Gramont¹³, Vincent Jachiet¹⁴, Gaëlle Leroux¹⁵, Matthieu Mahevas¹⁶, Julie Merindol¹⁷, Loïc Meudec¹⁸, Martin Michaud¹⁹, Morgane Mourguet²⁰, Héloïse Munos pons²¹, Yann Nguyen²², Bénédicte Oules²³, Thomas Papo²⁴, Jacques Pouchot²⁵, Sébastien Rivière¹⁴, Oscar Robert²⁶, Charles ronsin²⁷, Benjamin Rossi²⁸, Delphine Staumont-salle²⁹, Benjamin Terrier³⁰, Nathalie Tieule³¹, Vollmer Olivier³², Pierre Wolkenstein³³, Xavier Puéchal³⁴, Jean-David Bouaziz³⁵, Nicolas Dupin²³, Gilles Peytavin³⁶, Jean-Claude Alvarez³⁷, Luc Mouthon³⁸ and Alexis Régent³⁴, ¹Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, ²Dermatology, Hôpital Tenon, Paris, France, ³Medical Intensive Care Unit and MP3CV-EA7517, Amiens University Hospital, Amiens, France, Amiens, France, ⁴Service de Médecine Interne et Immunologie Clinique, Hôpital de La Conception, Marseille, Marseille, France, ⁵Department of Internal Medicine, CHU Bordeaux, Bordeaux, France., Bordeaux, France, ⁶Service de Cardiologie, Hôpitaux Saint-Antoine and Tenon, AP-HP, 75012 Paris, France., Paris, France, ⁷Department of Dermatology and Reference Center for Rare Skin Diseases (MAGEC), Saint-Eloi Hospital, University of Montpellier and INSERM U1058, Montpellier, France., Montpellier, France, ⁸Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ⁹Department of Dermatology, APHP, Bichat Hospital, Paris, France., Paris, France, ¹⁰AP-HP. Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose Inflammatoire, F-75013 Paris, France., Paris, France, ¹¹Department of Internal Medicine, Clinique Rhena, Strasbourg, France., Strasbourg, France, ¹²Assistance Publique Hôpitaux de Paris, Paris, France, ¹³Internal Medicine Departement, Saint Etienne, Saint Etienne, France, ¹⁴Service de médecine interne, AP-HP, Hôpital Saint Antoine, Sorbonne Universite, Paris, France., Paris, France, ¹⁵Service de Médecine Interne, AP-HP Hôpital Pitié-Salpêtrière, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, APHP, Mondor Hospital, Paris, France., Créteil, France, ¹⁷Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, ¹⁸Department of Rheumatology, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France., Kremlin Bicêtre, France, ¹⁹Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, ²⁰service de médecine interne CHU Toulouse RANGUEIL, Toulouse, France, ²¹Department of Internal Medicine, Saint-Etienne University Hospital, Saint-Etienne, France., Saint Etienne, France, ²²Université Paris Saclay, Clichy, Ile-de-France, France, ²³Dermatology Department, Cochin Hospital, Paris, France., Paris, France, ²⁴Université Paris Cité, Paris, France, ²⁵Service de médecine Interne, Centre National de Référence des syndromes drépanocytaires majeurs de l'adulte, AP-HP, Hôpital Européen Georges Pompidou, Paris, France, Paris, France, ²⁶Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Service de Pneumologie et Réanimation Médicale, Paris, France; [email protected]., Paris, France, ²⁷cHD Vendée, La Roche sur Yon, La Roche sur Yon, France, ²⁸Service de médecine interne, maladies infectieuses, Centre hospitalier intercommunal de Robert Ballenger, Aulnay-sous-bois, France., Aulnay-sous-bois, France, ²⁹Service de dermatologie, CHU de Lille, université de Lille, 59000 Lille, France., Lille, France, ³⁰Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ³¹Rhumatologie, Centre Hospitalier Universitaire Nice, Hôpital Pasteur, Nice, France, ³²Department of Immunology and Internal Medicine, Strasbourg University Hospital, Strasbourg, France., Strasbourg, France, ³³Department of Dermatology, National Referral Center for Neurofibromatosis, Henri Mondor University Hospital, Assistance Publique- Hôpitaux de Paris, Creteil, France., Créteil, France, ³⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ³⁵Dermatology, Hopital Saint-Louis, Paris, Île-de-France, France., Paris, France, ³⁶Service de Pharmacologie, Université Paris Cité, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France., Paris, France, ³⁷Service de Pharmacologie‑Toxicologie, Hôpital Raymond Poincaré, Groupe Hospitalier Universitaires AP-HP.Paris-Saclay, Garches, 92380, France, Paris, France, ³⁸Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: Levamisole, an imidazothiazole formerly used as an anthelmintic, is also used as a cutting agent to enhance the effects and duration of cocaine. In…
Abstract Number: 0117 • ACR Convergence 2024
Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Daniel Bar¹, Stanley Niznik², Shiri Spielman³, Rotem Semo-Oz⁴, Assaf Barg³, Sarina Levy-Mendelovich³, Gili Kenet², Nancy Agmon- Levin² and Irit Tirosh⁵, ¹Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, HaMerkaz, Israel, ²Sheba Medical Center, Tel Aviv, Israel, ³Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Tel Aviv, Israel, ⁴Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, Israel, ⁵Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Savyon, Israel
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous or microvascular thrombosis, obstetric morbidity and/or non-thrombotic manifestations. The 2023 ACR/EULAR APS…
Abstract Number: 0749 • ACR Convergence 2024
Age at Disease Onset Influences the Clinical Phenotype and Outcome of Patients with Takayasu Arteritis: Results from a Monocentric Cohort of 167 Patients
Alessandro Tomelleri¹, Corrado Campochiaro², Elena Baldissera³, Nicola Farina⁴, Marco Matucci-Cerinic⁵ and Lorenzo Dagna⁶, ¹Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³IRCCS San Raffaele Hospital, Milan, Italy, ⁴Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milan, Italy, ⁵University San Raffaele Milano, Milano, Milan, Italy, ⁶Ospedale San Raffaele, Milano, Italy
Background/Purpose: Takayasu arteritis (TAK) typically affects people between the ages of 20 and 40. However, disease onset can span across different age periods. Aim of…
Abstract Number: 0825 • ACR Convergence 2024
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study
Arielle Mendel¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Rosalie-Sélène Meunier⁹, Nataliya Milman¹⁰, Medha Soowamber¹¹, Jan Willem Cohen Tervaert¹², Elaine Yacyshyn⁴, Nader Khalidi¹³ and Christian Pagnoux¹⁴, ¹McGill University Health Centre, Montreal, QC, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Western University, Canada, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁹Hôpital Sacré-Coeur, Université de Montréal, Montreal, QC, Canada, ¹⁰the Ottawa Hospital, Ottawa, ON, Canada, ¹¹Mount Sinai Hospital, Woodbridge, ON, Canada, ¹²University of Alberta, Edmonton, Canada, ¹³McMaster University, Hamilton, ON, Canada, ¹⁴Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: To evaluate the effectiveness and safety of rituximab (RTX) biosimilars compared to the originator in Canadians with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…
Abstract Number: 1612 • ACR Convergence 2024
Arterial Involvement Distribution on 18FFDG PET-CT in Giant Cell Arteritis: Variances Based on Clinical Phenotype
paola Vidal¹, Javier Narvaez-García¹, Ivan Sánchez-Rodríguez¹, Aida Sabaté-Llobera¹, Montserrat Cortés-Romera¹, Judith Palacios², Pol Maymó³, Monserrat Roig Kim¹, Martí Aguilar Coll¹, Laia De Daniel¹ and Joan Miquel Nolla¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain
Background/Purpose: Current evidence shows that giant cell arteritis (GCA) is much more than a cranial disease, as it has a much broader and heterogeneous clinical…
Abstract Number: 1639 • ACR Convergence 2024
Ultrasound Fast-Track Giant Cell Arteritis Clinic Experience in the United States
Mark Matza¹, Sebastian Unizony² and Minna Kohler³, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Winchester, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Fast-track clinics utilizing ultrasound in the initial evaluation of patients with suspected giant cell arteritis (GCA) have been implemented throughout Europe allowing for rapid…
Abstract Number: 2490 • ACR Convergence 2024
Longitudinal Kidney Function Trajectories in Patients Enrolled in the Plasma Exchange and Glucocorticoids in ANCA-Associated Vasculitis Trial
Jennifer Hanberg¹, Yuqing Zhang², Andreas Kronbichler³, Anna Matyjek⁴, Carol McAlear⁵, Balazs Odler⁶, Lisa Uchida⁷, Duvuru Geetha⁸, Carmel Hawley⁹, David Jayne⁷, Michael walsh¹⁰, Peter Merkel⁵ and Zachary Wallace¹¹, and the PEXIVAS investigators, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Medical University Innsbruck and University of Cambridge, Innsbruck, Austria, ⁴Medical University of Lodz and Medical University Innsbruck, Lodz, Poland, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Medical University of Graz, Graz, Austria, ⁷University of Cambridge, Cambridge, United Kingdom, ⁸Johns Hopkins University, Baltimore, MD, ⁹Princess Alexandra Hospital and Translational Research Institute, Brisbane, Australia, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA-associated vasculitis (AAV) causes kidney damage, leading to a spectrum of chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Clinically distinct kidney function…
Abstract Number: 2516 • ACR Convergence 2024
Exome-Wide Rare Variant Association Study of Takayasu’s Arteritis
Yiming Luo¹, Zuoming deng², Kaitlin Quinn³, Keith Sikora⁴, Daniel Kastner⁵, Krzysztof Kiryluk¹, Amr Sawalha⁶, Peter Merkel⁷ and Peter Grayson⁸, and the Vasculitis Clinical Research Consortium, ¹Columbia University Irving Medical Center, New York, NY, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, ⁶University of Pittsburgh, Pittsburgh, ⁷University of Pennsylvania, Philadelphia, PA, ⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Takayasu’s arteritis (TAK) is a rare inflammatory disease primarily involving the aorta and its major branches. Multiple genetic association studies on common variants in…
Abstract Number: 0675 • ACR Convergence 2023
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
allyson egan¹, Pasupathy Sivasothy² and David Jayne³, ¹Trinity Health Kidney Centre, Tallaght University Hospital, Ireland, Dublin, Ireland, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0705 • ACR Convergence 2023
Sleep Disturbances in Patients with Vasculitis: Results of the Vasculitis Patient-Powered Research Network Sleep Study (SleepVasc)
Misa Tanaka¹, Saverio Stranges¹, Kathy Speechley¹, Osvaldo Espin Garcia¹, Molly Mason², Renee Borchin³, Cristina Burroughs³, Christine Yeung⁴, Indira Gurubhagavatula⁴, Christian Pagnoux⁵, Peter Merkel⁴ and Lillian Barra¹, ¹Western University, London, ON, Canada, ²Vasculitis Patient Powered Research Network, Philadelphia, PA, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Sleep deprivation and sleep disorders can impair health-related quality of life and increase the risk of chronic diseases, such as cardiovascular disease, and mental…
Abstract Number: 1061 • ACR Convergence 2023
Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Chani-mi Lee¹, Margaret Wang², Aarthi Rajkumar¹, Cassandra Calabrese³ and Leonard Calabrese³, ¹University Hospital, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known…
Abstract Number: 1558 • ACR Convergence 2023
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Didar Ucar¹, Basak Ecem Bircan², Nigar Rustamli², Bilge Batu Oto¹, Vedat Hamuryudan³, Sinem Nihal Esatoglu³ and Gulen Hatemi³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells (VC) on slit lamp examination at the time of diagnosis. However, the…
Abstract Number: 1889 • ACR Convergence 2023
Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis
HUGO AVALOS BOGADO¹, GUSTAVO AÑEZ STURCHIO², Ernesto Trallero-Araguas³, Esther Espartal López⁴, sebastián Sandoval Moreno¹, daniela Ulloa Navas⁵ and Juan José De Agustín De Oro², ¹Rheumatology Department Vall d'Hebrón University Hospital, Barcelona, Spain, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁴Vall Hebron University Hospital, Rheumatology Department, Barcelona, Spain, ⁵Rheumatology Department, Vall Hebron University Hospital, Barcelona, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most prevalent type of primary systemic vasculitis among individuals aged 50 and above. Imaging techniques such as ultrasound…
Abstract Number: 2401 • ACR Convergence 2023
A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis
Colm Kirby¹, Sharon Cowley², Rachael Flood¹, Ronan Mullan¹, Grainne Murphy³ and David Kane⁴, ¹Tallaght University Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Cork University Hospital, Cork, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: In recent years, Temporal Artery US (TAUS) incorporating Axillary Artery US (AAUS) has become a reliable alternative to biopsy for diagnosing GCA but studies…
Abstract Number: 2425 • ACR Convergence 2023
Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data
Amadeia Rector¹, Julia Simard², Gary Shaw³ and Audra Horomanski⁴, ¹Stanford University, San Francisco, CA, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Systemic vasculitides are rare, heterogeneous, inflammatory disorders associated with high morbidity and mortality. Recent management and therapeutic advances have improved life expectancy and reproductive…

« Previous Page
1
…
6
7
8
9
10
…
35
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].